<div id="readability-page-1"><div> <div> , /PRNewswire/ -- China Medical University Hospital (CMUH), under the leadership of Superintendent Dr. Cho Der-Yang, announced a major breakthrough in exosome-based drug delivery, achieved in collaboration with Ever Supreme Bio Technology and Shine-On Biomedical. Building on their prior success in developing HLA-G–targeted exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS). Continue Reading <div> <div> <div> <div> <figure> <img id="imageid_2" src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/> <figcaption> The research team led by Dr. Cho Der-Yang, Superintendent of China Medical University Hospital, in collaboration with Ever Supreme Bio Technology and Shine Out Biotechnology, jointly unveiled the world’s first actively navigated αDAT-EV Brain-Targeting Exosome Platform. (From left to right: Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology; Academician Dr. LIN Jaung-Geng of Academia Sinica; Dr. Cho Der-Yang, Superintendent of China Medical University Hospital.) </figcaption> </figure> </div> </div> </div> </div> The result is a world-first, actively navigated brain-targeting exosome platform—αDAT-EV—capable of transporting therapeutic agents across the blood–brain barrier (BBB) and precisely directing them to impacted neural regions implicated in Parkinson's disease (PD). This landmark research has been published in the leading international publication Journal of Nanobiotechnology. αDAT-EV: The World's First Actively Navigated Brain-Targeting Exosome Drug Delivery Platform Dr. Cho noted that as global populations age, the prevalence of neurodegenerative diseases such as Parkinson's disease continues to rise sharply. Yet for decades, neurological therapeutics have faced a formidable obstacle: nearly 98% of drugs fail to effectively cross the blood–brain barrier, severely limiting treatment efficacy and slowing progress in neurological medicine.To overcome this bottleneck, CMUH researchers, together with Shine Out Bio Technology, employed genetic engineering techniques to modify antibody fragments on the surface of exosomes that recognize the dopamine transporter (DAT). This innovation enables αDAT-EVs to actively identify and target dopaminergic neurons—effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions while improving the bioavailability of small-molecule drugs.A Nano-Scale &#34;Medicinal Guide&#34;: Reimagining Curcumin with Modern BiotechnologyAcademician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a &#34;food-medicine homolog,&#34; is known for its antioxidant and anti-inflammatory properties. Modern research has confirmed its ability to repair neuronal damage at the source and clear pathological protein aggregates. Despite its promise, the benefits of curcumin have historically been &#34;visible but unattainable&#34;: poor water solubility, rapid metabolism, and inability to cross the blood–brain barrier have resulted in negligible brain concentrations in clinical settings.Through the αDAT-EV brain-targeting platform, curcumin can now be actively guided into the brain, functioning as a modern nano-scale medicinal guide. This breakthrough exemplifies the integration of traditional medical wisdom with cutting-edge biotechnology, and stands as a compelling model for the scientific modernization of traditional medicine.Multi-Pathway Cellular Repair Demonstrates Strong Translational PotentialAccording to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using αDAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both cellular and animal models, highlighting the platform's potential as a next-generation nano drug carrier:1. Precision TargetingThe platform significantly enhances drug penetration across the BBB and enriches therapeutic agents in key Parkinson's disease-related regions, including the substantia nigra and ventral tegmental area.2. Activation of Repair MechanismsαDAT-EVs trigger cellular autophagy-lysosomal pathways and mitochondrial repair mechanisms, effectively clearing pathological α-synuclein aggregates and alleviating disease symptoms.3. Immune ModulationThe treatment promotes a shift in brain microglia from a pro-inflammatory to a reparative phenotype, indicating reduced neuroinflammation.4. Improved Motor FunctionParkinson's disease animal models exhibited marked recovery in motor coordination, underscoring the platform's strong clinical translation potential.A Versatile Exosome Platform Expanding the CNS Therapeutic FrontierThe αDAT-EV brain-targeting exosome platform is highly scalable and expandable. While initially developed to deliver cytotoxic payloads against cancer cells, it now demonstrates the ability to transport therapeutic agents for neuronal repair.This innovation offers a transformative solution for neurodegenerative diseases long constrained by the blood–brain barrier. Looking ahead, the platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease, stroke, and other CNS disorders, significantly advancing the fields of neurology and precision medicine.In the fourth quarter of 2025, Ever Supreme Bio Technology announced the acquisition of 100% equity in Shine Out Bio Technology through a share-exchange transaction, resulting in Shine Out becoming a wholly owned subsidiary. The effective date of the share swap is January 13, 2026. General Manager Mr. Huang Wen-Liang stated that the acquisition creates strong synergies between the two companies' technology platforms and therapeutic focus areas, accelerating the advancement of cell-based therapies into an internationally competitive pharmaceutical industry regulated under Taiwan's Regenerative Medicine Act and the Regenerative Medicine Products Act.Under Taiwan's Regenerative Medicine Dual-Act framework, beginning January 1, 2026, regenerative products targeting life-threatening or severely disabling diseases may apply for a conditional five-year marketing authorization upon completion of Phase II clinical trials demonstrating safety and preliminary efficacy. This pathway significantly accelerates commercialization and promises improved therapeutic options for aging societies worldwide.Note 1: Shine Out Biotechnology is dedicated to developing next-generation exosome drug delivery platforms. Leveraging proprietary genetic engineering and manufacturing technologies, the company addresses longstanding challenges in exosome yield and targeting specificity. With &#34;precision delivery and regenerative repair&#34; at its core, Shine-On aims to become a global leader in exosome-based therapeutics.Note 2: Journal of Nanobiotechnology.SOURCE China Medical University Hospital<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2"/></div> </div></div>

China Medical University Hospital (CMUH) has announced a breakthrough in exosome-based drug delivery for Parkinson's disease, collaborating with Ever Supreme Bio Technology and Shine-On Biomedical. They developed the αDAT-EV platform, which can transport therapeutic agents across the blood-brain barrier, targeting affected neural regions. This innovation allows curcumin, known for its neuroprotective properties, to be effectively delivered to the brain. Preclinical studies show promising results in enhancing drug penetration, activating repair mechanisms, and improving motor function in animal models. The platform has potential applications in various CNS disorders and is scalable for future therapies.

prnewswire

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

iShares Biotechnology ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Guotai CSI Bio-medicine ETF

Hwabao WP CSI Pharmaceuticals ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

iShares US Pharma

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

SPDR S&P Biotech

ChinaAMC SSE STAR Biology and Medicine ETF

07:43 ET
			
			
				CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

07:43 ET CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease